SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations
News
Early use of CARVYKTI shows lasting remissions in multiple myeloma
Johnson & Johnson reports phase 3 data highlighting durable outcomes and immune fitness benefits
Bayer begins phase 2 trial of new Alport syndrome therapy
New study to test Sema3A antibody in rare genetic kidney disease
Johnson & Johnson wins EU approval for new gMG treatment
Nipocalimab authorised for adults with antibody-positive generalised myasthenia gravis
Pharvaris reports positive phase 3 results for HAE treatment
Deucrictibant shows rapid symptom relief and strong safety profile in RAPIDe-3 study
AlzeCure secures EU grant for Alzheimer’s drug trial
Funding supports phase 2 study of NeuroRestore ACD856 in patients
Vandria reports positive phase 1 data for Alzheimer’s drug candidate
Company highlights safety and target engagement results for VNA-318 at CTAD meeting
HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis
Bimekizumab offers fresh option for patients with chronic conditions
MSD to acquire Cidara after positive phase 2b trial results
hVIVO celebrates landmark deal highlighting its role in advancing influenza therapy
eXmoor Pharma and Royal Free London link to strengthen UK gene therapy
Collaboration aims to streamline manufacturing linking nhs early-phase expertise
Alzheimer’s prevention charity pioneers research on nutrition biomarkers to detect risk
Foundation’s test to be used in Oxford-led blood biomarker trial
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
First long-acting therapy with three-monthly dosing to target root cause of cardiac disease
FDA approves Keytruda and Keytruda Qlex with Padcev for bladder cancer
First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients
Academy and Wellcome strengthen partnership with £27m agreement to boost UK health research
Five-year deal aims to support UK biomedical talent and drive collaboration across sectors
Bayer’s asundexian shows promise in landmark phase 3 stroke study
Positive topline results highlight potential new option for secondary stroke prevention
